**TCIRG1-Associated Congenital Neutropenia**

Vahagn Makaryan, Elisabeth A. Rosenthal, Audrey Anna Bolyard, Merideth L. Kelley, Jennifer E. Below, Michael J. Bamshad, Kathryn M. Bofferding, Joshua D. Smith, Kati Buckingham, Laurence A. Boxer, Julia Skokowa, Karl Welte, Deborah A. Nickerson, Gail P. Jarvik, and David C. Dale

**Department of Medicine, Divisions of GIM, University of Washington, Seattle, Washington; Department of Medicine, Medical Genetics, University of Washington, Seattle, Washington; Division of Epidemiology, Human Genetics & Environmental Sciences, University of Texas School of Public Health, Houston, Texas; Department of Genome Sciences, University of Washington, Seattle, Washington; Department of Pediatrics, University of Washington, Seattle, Washington; Pediatric Hematology Oncology, University of Michigan, Ann Arbor, Michigan; Department of Molecular Hematopoiesis, Kinderklinik, Medizinische Hochschule, Hannover, Germany**

Communicated by Garry R. Cutting.

Received 29 August 2013; accepted revised manuscript 28 March 2014. Published online 17 April 2014 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22563

**ABSTRACT:** Severe congenital neutropenia (SCN) is a rare hematopoietic disorder, with estimated incidence of 1 in 200,000 individuals of European descent, many cases of which are inherited in an autosomal dominant pattern. Despite the fact that several causal genes have been identified, the genetic basis for >30% of cases remains unknown. We report a five-generation family segregating a novel single nucleotide variant (SNV) in TCIRG1. There is perfect cosegregation of the SNV with congenital neutropenia in this family; all 11 affected, but none of the unaffected, individuals carry this novel SNV. Western blot analysis showed reduced levels of TCIRG1 protein in affected individuals, compared to healthy controls. Two unrelated patients with SCN, identified by independent investigators, are heterozygous for different, rare, highly conserved, coding variants in TCIRG1. 


**KEY WORDS:** TCIRG1; congenital neutropenia; SCN; V-ATPase.

Severe congenital neutropenia (SCN) is a hematological condition characterized by blood neutrophil counts (absolute neutrophil counts or ANC) < 0.5 × 10^9/L and recurrent bacterial infections usually beginning very early in childhood. In 1956, Kostmann described an autosomal recessive form of SCN [Kostmann, 1956]. This recessive form of SCN is now attributable to mutations in HAX1, a Bcl-2-family-related gene [Carlsson and Fasth, 2001; Klein et al., 2007]. Much more frequently, SCN is an autosomal dominant disorder caused by mutations in ELA2, a gene encoding the protein neutrophil elastase, an enzyme of the neutrophil’s primary granules.

Additional Supporting Information may be found in the online version of this article.

†These authors contributed equally to this work as first authors.

Contract grant sponsors: NIH (1U54HG006493); NIH/NIAID (5R24AI049393-09 and T32 GM007454); Washington State Life Sciences for University of Washington Northwest (3C41PR063180-01A1); Center for Mendelian Genomics.

Communicated by Garry R. Cutting.

Additional Supporting Information may be found in the online version of this article. [Horrwitz et al., 1999; Dale et al., 2000]. About 60% of cases of SCN in the North American population are attributable to ELA2 mutations [Xia et al., 2009]. Mutations in other genes, for example, genes affecting glucose homeostasis (SLC37A4, G6PC3), lysosomal function (LYST, RAB27A, ROBLD3/p14, AP3B1, VPS13B), ribosomal proteins (SBDS, RMRP), mitochondrial proteins (HAX1, AK2, TAZ), immune functions (STK4, GF11, CXC4), and X-linked (WAS), also cause neutropenia [Boztug and Klein, 2009]. Many families with autosomal dominant SCN have no identifiable mutation, suggesting that other SCN genes exist. We used high-density SNP chips to detect identity-by-descent (IBD) regions among affected in a large SCN family, followed by exome sequencing to identify coding single nucleotide variants (SNVs) in the IBD regions. This strategy implicates TCIRG1 (MIM# 604592) as a novel SCN gene.

Primary analysis was performed on 18 members of a single five-generation family of European-American descent ascertained for neutropenia (ANC < 1.5 × 10^9/L) and severe neutropenia (ANC < 0.5 × 10^9/L) utilizing DNA extracted from peripheral blood mononuclear cells and saliva (Supp. Fig. S1). In 13 of the affected individuals, the median ANC was 0.524 × 10^9/L, with range 0.074–1.1 × 10^9/L and six of the 13 had severe neutropenia based on all available clinical data. For eight unaffected members, the median was 3.819 × 10^9/L, with range 2.343–6.5 × 10^9/L. There were no family members with congenital anomalies of the heart, lungs, neurologic, gastrointestinal, or urogenital systems and no history of bone disease, frequent fractures, or hearing loss. Two patients had prominent hemangiomas that became more prominent during treatment with granulocyte colony stimulating factor. Genes associated with SCN, that is, ELA2, HAX1, G6PC3, WAS, and GF11, had been previously sequenced in the index case for this family and no likely causal variants were identified [Xia et al., 2009].

IBD analysis carried out using fast IBD from the software package BEAGLE 3.3.2 [Browning and Browning, 2011] on SNPs from the ∼200 K SNP HumanCytoSNP-12 BeadChip, reduced the possible regions underlying the shared phenotype to chromosomes (chr.) 3 and 11. The five affected cousins in the lowest generations (IDs 410, 411, 504, 505, and 510) shared regions IBD on chrs. 1, 3, and 11. The unaffected cousin (ID 412) also shared the region on chr. 1, and parts of the regions on chr. 3q and 11q. This narrowed the regions of interest to chr. 3 (between 193801183bp and the q terminus, map build GRCh37/hg18) and 11 (66842469–76462540 bp).

A search of the exome sequences of IDs 410 and 504 in these regions on chrs. 3 and 11 led to two genes of interest. Two novel
protein were used. A polyclonal antibody developed against the N-terminal cytoplasmic domain of human TCIRG1-isoa protein (Santa Cruz Biotechnology, Dallas, TX) detects reduced amounts of ~45 kDa TCIRG1 product fragment in all three individuals harboring the ARG736SER mutation, compared to healthy controls (Fig. 1, B1). This protein fragment is most likely the shorter TCIRG1-isoa. A monoclonal antibody raised against the partial recombinant TCIRG1-isoa 121aa–220aa (Abnova, Taipei City, Taiwan) detects a distinct protein band at ~120 kDa. Presumably, this is the full-length TCIRG1-isoa protein, with similar expression levels in both affected individuals and healthy controls (Fig. 1, B2). In addition, we have performed TCIRG1 transcripts analysis (data not shown) by RT–PCR using the total RNA from the same source as the WB analysis and found no alterations in mRNA expression compared to the controls.

It is unclear how the p.Arg736Ser mutation causes a reduction of the shorter isoform, but not the longer isoform a. It is possible that the reduced protein in our patients is one of the not yet fully characterized novel isoforms of TCIRG1 as previously reported by Smirnova et al. (2005). Apparently, this missense SNV within exon 18 does not cause any detectable alterations in the TCIRG1 transcripts. However, the change does affect the observed level of protein. The arginine is changed to serine, a major shift based on amino acids molecular size and properties, and this change is located at an evolutionary highly conserved site. It is possible that the reduced levels of protein is due to posttranslational folding defects of the mutant protein and subsequent endoplasmic reticulum associated degradation and elimination [Waters, 2001; Meusser et al., 2005; Ding and Yin, 2008]. The p.Arg736Ser mutation in this family has never been reported, either as a variant causal for autosomal recessive malignant osteopetrosis (arOP) or associated with neutropenia.

As a follow-up, TCIRG1 mutational analysis in 20 unrelated SNC individuals known to be negative for mutations in the known SCN genes was conducted by standard PCR amplification using HotStarTaq DNA Polymerase (Qiagen, Inc., Valencia, CA) and custom-designed primer sets. Products of PCR amplification were purified with QIAquick PCR Purification Kit (Qiagen, Inc.). The amplifications were sequenced in the forward and reverse directions using BigDye Terminator V3.1 Cycle Sequencing Kits (Applied Biosystems, Foster City, CA) and a capillary DNA analyzer (Applied Biosystems). Primer set sequences will be provided upon request. Two SNVs in two individuals were implicated in SCN based on microsatellite analysis and elimination [Waters, 2001; Meusser et al., 2005; Ding and Yin, 2008].

Two different commercially available antibodies against TCIRG1 (no rsID and does not exist in the Exome Variant Server (EV) at SeattleSNPs [http://evs.gs.washington.edu/EVS/] as of April 2013) missense SNVs were shared by these two exome sequenced affected in the genes TCIRG1 and MAP6 on chr. 11 (Table 1). Both SNVs are conserved across mammals (genome evolutionary rate profiling (GERP) score > 2) [Adzubei et al., 2010]. However, only TCIRG1 is expressed in blood tissue (monocytes) [Pontius et al., 2003] and is directly involved in T–cell activation [Utku et al., 1998], making it the likely etiological candidate. The TCIRG1 SNV NM_006019.3:c.2206C>A (ClinVar SCV001200004), which causes the amino acid change—p.Arg736Ser (Fig. 1A), has a GERP score of 3.78. Sanger sequencing of 20 members (14 affected and six unaffected) of this family reveals a perfect segregation of the novel TCIRG1 SNV with affection status (Fig. 1A).

Known congenital neutropenia genes (ELA2, HAX1, G6PC3, WAS, and GFI1) were checked for sequence variation that might have been missed by the earlier Sanger sequencing, and no known causal or novel variation was observed among these two affected individuals. Western blot analysis confirmed a possible deregulatory involvement of TCIRG1 protein in the pathogenesis of neutropenia in this family. Previous studies have shown that Western blot analysis from patient-derived cells harboring homozygous mutations in this gene has undetectable concentrations of TCIRG1 protein products [Frattni et al., 2000]. TCIRG1, through alternate splicing, gives rise to two separate proteins: Isoforms (-iso) a and b previously known as OC-116 and TIRC7, respectively [Heinemann et al., 1999; Frattni et al., 2000; Susani et al., 2004]. TCIRG1-isoa lacks the first five exons of the longer variant, TCIRG1-isoa. We performed Western blot analysis using lysed peripheral blood mononuclear cells from three affected individuals of this family and healthy volunteers. Two different commercially available antibodies against TCIRG1 proteins were used. A polyclonal antibody developed against the N-terminal cytoplasmic domain of human TCIRG1-isoa protein (Santa Cruz Biotechnology, Dallas, TX) detects reduced amounts of ~45 kDa TCIRG1 product fragment in all three individuals harboring the ARG736SER mutation, compared to healthy controls (Fig. 1, B1). This protein fragment is most likely the shorter TCIRG1-isoa. A monoclonal antibody raised against the partial recombinant TCIRG1-isoa 121aa–220aa (Abnova, Taipei City, Taiwan) detects a distinct protein band at ~120 kDa. Presumably, this is the full-length TCIRG1-isoa protein, with similar expression levels in both affected individuals and healthy controls (Fig. 1, B2). In addition, we have performed TCIRG1 transcripts analysis (data not shown) by RT–PCR using the total RNA from the same source as the WB analysis and found no alterations in mRNA expression compared to the controls.

It is unclear how the p.Arg736Ser mutation causes a reduction of the shorter isoform, but not the longer isoform a. It is possible that the reduced protein in our patients is one of the not yet fully characterized novel isoforms of TCIRG1 as previously reported by Smirnova et al. (2005). Apparently, this missense SNV within exon 18 does not cause any detectable alterations in the TCIRG1 transcripts. However, the change does affect the observed level of protein. The arginine is changed to serine, a major shift based on amino acids molecular size and properties, and this change is located at an evolutionary highly conserved site. It is possible that the reduced levels of protein is due to posttranslational folding defects of the mutant protein and subsequent endoplasmic reticulum associated degradation and elimination [Waters, 2001; Meusser et al., 2005; Ding and Yin, 2008]. The p.Arg736Ser mutation in this family has never been reported, either as a variant causal for autosomal recessive malignant osteopetrosis (arOP) or associated with neutropenia.

As a follow-up, TCIRG1 mutational analysis in 20 unrelated SNC individuals known to be negative for mutations in the known SCN genes was conducted by standard PCR amplification using HotStarTaq DNA Polymerase (Qiagen, Inc., Valencia, CA) and custom-designed primer sets. Products of PCR amplification were purified with QIAquick PCR Purification Kit (Qiagen, Inc.). The amplifications were sequenced in the forward and reverse directions using BigDye Terminator V3.1 Cycle Sequencing Kits (Applied Biosystems, Foster City, CA) and a capillary DNA analyzer (Applied Biosystems). Primer set sequences will be provided upon request. Two SNVs in two individuals were implicated in SCN based on minor allele frequency (MAF) and GERP score. The first mutation,
rs139617644:G>A, [described in Sobacchi et al., 2001] is located in the acceptor splice site of intron 14, and predicted to alter the splicing (data not shown). This SNP occurs in only three of 12,988 chromosomes in EVS (July 2013), has GERP = 4.12, and is highly conserved among vertebrates [Siepel et al., 2005]. The second mutation, rs186758849:G>A, causes p.GLY160GLU and is located in exon 5. This SNP has MAF = 0.006, is predicted to be possibly damaging [Adzhubei et al., 2010], and is highly evolutionarily conserved (GERP = 4.42). No other SNVs predicted to alter protein structure were found.

TCIRG1 is located at 11q13, consists of 20 exons, and through alternate splicing gives rise to two main isoforms: TCIRG1-isoa and TCIRG1-iso6. TCIRG1-isoa is a full-length isoform and encodes a3 subunit of vacuolar H+-ATPase. TCIRG1-iso6 is a shorter isoform, lacking the first five exons of the longer isoform. Vacular H+-ATPases are well-described large protein complexes composed of two main functional domains: peripheral V_i and membrane-associated V_o. Both domains consist of multiple subunits. V-ATPases are involved in regulation of the pH of intracellular compartments and organelles of eukaryotic cells, including the pH of neutrophil phagocytic vacuoles [Supp. Fig. S2] [Nanda et al., 1996; Yao et al., 2007; Hinton et al., 2009].

TCIRG1-isoa is highly expressed in osteoclasts and is essential for bone resorption. Homozygous or compound heterozygous mutations in this gene cause arOP characterized by bone resorption defect due to osteoclast malfunction through impairing acidification at the ruffle border interface between osteoclasts and bone [Frattini et al., 2000]. More than 50% of all cases of arOP are attributable to mutations in TCIRG1, and more than 90 different mutations have been described.

Although congenital neutropenia due to mutations in TCIRG1 have not been previously described, there is biological evidence for a role in SCN. Experimental data reveals that arginine 735 in TCIRG1 protein (homologous to human ARG736) is essential for proton translocation [Kawasaki-Nishi et al., 2001]. Studies in mice have shown that although a homozygous mutation at amino acid 740 (homologous to human amino acid 736) is lethal in mice, a heterozygous mutation of the V-ATPase a3 subunit R740S causes dominant negative osteopetrosis [Ochotny et al., 2011]. As mentioned above, through an alternative splicing and usage of an alternative initiation codon in exon 7, TCIRG1 codes another protein, TIRC7-iso6, which is a T-cell-specific membrane protein demonstrated to play an essential role for T-lymphocyte activation and immune response. RNA interference to silence TCIRG1-iso6, Ap6i +/- mice reduced inflammatory responses in a mouse model of periodontal disease and decreased osteoclasts and monocytes [Jiang et al., 2013]. However, these reports do not comment on blood neutrophil counts or granulocytopenia in the mice. Although the secondary hematological consequences of osteopetrosis are well known, there are no comments in the literature on blood neutrophil counts or granulocytopenia in individuals harboring heterozygous variants in this gene. Interestingly, there are multiple novel splice variants of TCIRG1 with unknown functional effects and the proteins are expressed in numerous human tissues (heart, liver, kidney, lung, and pancreas) [Susani et al., 2004; Smirnova et al., 2005].

It is possible that TCIRG1 is relevant to SCN through other pathways. Besides regulating bone resorption, osteoclasts regulate osteoblasts, a cell population implicated in hematopoietic stem cell maintenance [Zhang et al., 2002; Calvi et al., 2003]. Indeed, osteoclast activation has been implicated in the mobilization of hematopoietic progenitor cells from the bone marrow to blood [Kollet et al., 2006]. Moreover, prior published studies of RNA profiling of murine osteoblasts indicate that TCIRG1 is also expressed in this cell population [Eash et al., 2010]. Thus, it is possible that TCIRG1 p.Arg736Ser may indirectly disrupt granulopoiesis by altering the bone marrow microenvironment. Alternatively, TCIRG1 products are broadly expressed in hematopoietic cells. RNA expression profiling of granulocytic precursors from healthy donors suggests that TCIRG1-isoa is highly expressed in promyelocytes. Thus, TCIRG1 p.Arg736Ser may also directly act on granulocytic precursors to impair their differentiation or maturation. Further studies will be directed to defining the mechanisms for neutropenia and the importance of the vATPases in maintaining the integrity of the pathway for neutrophil production and deployment. Understanding the pathogenesis of TCIRG1-associated neutropenia will require several methodological approaches and more studies involving both individual patients and families.

Acknowledgments

Sequencing was provided by the University of Washington Center for Mendelian Genomics (UW CMG), funded by NIH grant 1U54HG006493 to Drs. Debbie Nickerson, Jay Shendure, and Michael Bamshad.

Disclosure statement: The authors declare no conflict of interest.

References


